Drugs for the treatment of malaria in the Kingdom of Saudi Arabia

Saudi Medical Journal

Volumn 34, Issue 6, 2013, Pages 569-578

  Nzila, Alexis ^a   Al Zahrani, Ibrahim ^b  

^a KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^b MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; CHLOROQUINE PLUS PRIMAQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTIMALARIAL DRUG RESISTANCE; BRADYCARDIA; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ECG ABNORMALITY; EOSINOPHILIA; EPIDERMOLYSIS; ERYTHEMA NODOSUM; ERYTHRODERMA; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; IMPORT DISEASE; LOADING DRUG DOSE; MALARIA; MALARIA FALCIPARUM; NAUSEA; NEUTROPENIA; PHOTOSENSITIVITY DISORDER; PLASMODIUM VIVAX MALARIA; PRURITUS; RETICULOCYTOPENIA; REVIEW; SAUDI ARABIA; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTE COUNT; TINNITUS; VISUAL DISORDER; VOMITING; WEAKNESS;

ANIMALS; ANTIMALARIALS; HUMANS; MALARIA; PLASMODIUM; SPECIES SPECIFICITY;

EID: 84879164739     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Eisele TP, Larsen DA, Walker N, Cibulskis RE, Yukich JO, Zikusooka CM, et al. Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001-2010. Malar J 2012; 11: 93.
2. Korenromp EL. Lives saved from malaria prevention in Africa- -evidence to sustain cost-effective gains. Malar J 2012; 11: 94.
3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379: 413-31.
4. Ministry of Health. The National Policy of Malaria Case Management in the Kingdom of Saudi Arabia. Riyadh (KSA): Abakar Printing Co.; 2008.
5. Al-Tawfiq JA. Epidemiology of travel-related malaria in a non-malarious areas in Saudi Arabia. Saudi Med J 2006; 27: 1781-1782.
6. Bashwari LA, Mandil AM, Bahnassy AA, Al-Shamsi MA, Bukhari HA. Epidemiological profile of malaria in a university hospital in the eastern region of Saudi Arabia. Saudi Med J 2001; 22: 133-138.
7. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7: 864-874.
8. Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 2006; 57: 1043-1054.
9. Zarocostas J. WHO unveils plan to stop artemisinin resistance "dead in its tracks". BMJ 2011; 342: d211.
10. Woodrow CJ, Bustamante LY. Mechanisms of artemisinin action and resistance: wider focus is needed. Trends Parasitol 2011; 27: 2-3.
11. Price RN, Douglas NM, Anstey NM, von Seidlein L. Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis 2011; 24: 578-585.
12. Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011; 10: 351.
13. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009; 22: 508-534.
14. Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE. Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends Parasitol 2005; 21: 334-339.
15. Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol 2005; 21: 292-298.
16. Shen WJ, Thiero M. [Coartem and fansimef in the treatment of falciparum malaria]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2006; 24: 26. Chinese
17. Peters W. Resistance in human malaria III: dihydrofolate reductase inhibitors. Chemotherapy and Drug Resistance in Malaria. London (UK): Academy Press Limited; 1987. p. 593-827.
18. Al Harthi SA. Detection of drug resistance markers for chloroquine and pyrimethamine-sulfadoxine in Jazan area, Saudi Arabia using PCR and restriction digestion. J Egypt Soc Parasitol 2007; 37: 17-30.
19. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009; 7: 999-1013.
20. Allen EN, Little F, Camba T, Cassam Y, Raman J, Boulle A, et al. Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Malar J 2009; 8: 141.
21. Bell DJ, Nyirongo SK, Mukaka M, Zijlstra EE, Plowe CV, Molyneux ME, et al. Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS One 2008; 3: e1578.
22. Bukirwa H, Critchley J. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. Cochrane Database Syst Rev 2006: CD004966.
23. Obonyo CO, Taylor W, Ekvall H, Kaneko A, Ter Kuile F, Olliaro P, et al. Effect of artesunate plus sulfadoxine-pyrimethamine on haematological recovery and anaemia, in Kenyan children with uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol 2007; 101: 281-295.
24. Charle P, Berzosa P, Descalzo MA, de Lucio A, Raso J, Obono J, et al. Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for Uncomplicated falciparum Malaria in Equatorial Guinea (Central Africa). J Trop Med 2009; 2009: 781865.
25. Bonnet M, Broek I, van Herp M, Urrutia PP, van Overmeir C, Kyomuhendo J, et al. Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar J 2009; 8: 192.
26. Tall A, Rabarijaona LP, Robert V, Bedja SA, Ariey F, Randrianarivelojosia M. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxine-pyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union. Acta Trop 2007; 102: 176-181.
27. Seboxa T, Mao P, Pinchouk N, Anbessie J, Alemu H, Diro E. Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia. Ethiop Med J 2010; 48: 285-291.
28. Mohamed AA, Mahgoub HM, Magzoub M, Gasim GI, Eldein WN, Ahmed AA, et al. Artesunate plus sulfadoxine/ pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans R Soc Trop Med Hyg 2009; 103: 1062-1064.
29. World Health Organization. WHO The treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.
30. Ibrahium AM, Kheir MM, Osman ME, Khalil IF, Alifrangis M, Elmardi KA, et al. Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. Ann Trop Med Parasitol 2007; 101: 15-21.
31. Kolaczinski K, Leslie T, Ali I, Durrani N, Lee S, Barends M, et al. Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP. PLoS One 2012; 7: e28957.
32. Afsharpad M, Zakeri S, Pirahmadi S, Djadid ND. Molecular monitoring of Plasmodium falciparum resistance to antimalarial drugs after adoption of sulfadoxine-pyrimethamine plus artesunate as the first line treatment in Iran. Acta Trop 2012; 121: 13-18.
33. Campbell P, Baruah S, Narain K, Rogers CC. A randomized trial comparing the efficacy of four treatment regimens for uncomplicated falciparum malaria in Assam state, India. Trans R Soc Trop Med Hyg 2006; 100: 108-118.
34. Saha P, Guha SK, Das S, Mullick S, Ganguly S, Biswas A, et al. Comparative efficacy of Artemisinin Combination Therapies (ACTs) in P. falciparum malaria and polymorphism of PfATPase6, Pfcrt, Pfdhfr and Pfdhps genes in tea gardens of Jalpaiguri district, India. Antimicrob Agents Chemother 2012; 56: 2511-2517.
35. Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 1979; 73: 15-17.
36. Snounou G, White NJ. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol 2004; 20: 333-339.
37. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, et al. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother 2003; 47: 1514-1521.
38. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol 2007; 23: 213-222.
39. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJ, et al. Sulfadoxine-pyrimethamine, chlorproguanildapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007; 297: 2201-2209.
40. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010; 10: 405-416.
41. Wells TN, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol 2010; 26: 145-151.
42. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS et al. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. Acta Trop 2011; 117: 69-75.
43. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN. Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria. Adv Parasitol 2012; 80: 271-300.
44. Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, et al. Efficacy and Safety of Artemether-Lumefantrine in the Treatment of Acute, Uncomplicated Plasmodium falciparum Malaria: A Pooled Analysis. Am J Trop Med Hyg 2011; 85: 793-804.
45. Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisininpiperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 2011; 10: 231.
46. Valecha N, Mohanty S, Srivastava P, Sharma S, Tyagi P, Bergqvist Y, et al. Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine. Am J Trop Med Hyg 2012; 86: 395-397.
47. Valecha N, Srivastava P, Mohanty SS, Mittra P, Sharma SK, Tyagi PK, et al. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar J 2009; 8: 107.
48. Nzila A, Okombo J, Ohuma E, Al-Thukair A. Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine. J Antimicrob Chemother 2012; 67: 2309-2315.
49. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42: 1570-1577.
50. Bassat Q. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis 2011; 5: e1325.
51. Okombo J, Ohuma E, Picot S, Nzila A. Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol Biochem Parasitol 2011; 177: 77-82.
52. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-725.
53. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647-57.
54. Sinclair D, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2011; 3: CD005967.
55. Chen C, Zheng X. Development of the new antimalarial drug pyronaridine: a review. Biomed Environ Sci 1992; 5: 149-160.
56. Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26: 946-953.
57. Ramharter M, Kurth F, Schreier AC, Nemeth J, Glasenapp I, Belard S, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008; 198: 911-919.
58. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemetherlumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375: 1457-1467.
59. Anonymous. Annex I: Summary of product characteristics. (Access 23 May 2013). Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129288.pdf
60. Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, et al. In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother 2010; 54: 5146-5150.
61. Fu S, Xiao SH. Pyronaridine: A new antimalarial drug. Parasitol Today 1991; 7: 310-313.
62. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011; 6: e14501.
63. Guan WB, Huang WJ, Zhou YC, Pan WQ. [Effect of piperaquine and hydroxypiperaquine on a chloroquine-resistant strain of Plasmodium falciparum]. Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1983; 1: 88-90.
64. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs 2005; 65: 75-87.
65. Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet 2004; 363: 18-22.
66. Gargano N, Cenci F, Bassat Q. Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties. Trop Med Int Health 2011; 16: 1466-1473.
67. D'Alessandro U. Progress in the development of piperaquine combinations for the treatment of malaria. Curr Opin Infect Dis 2009; 22: 588-592.
68. Anonymous. Annex I: Summary of product characteristics. (Access 23 May 2013) Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf
69. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113: 1084-1092.
70. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379: 1960-1966.
71. Ding XC, Beck HP, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 2011; 27: 73-81.
72. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-467.
73. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424: 957-961.
74. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother 2010; 54: 3842-3852.
75. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012; 336: 79-82.
76. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A 2013; 110: 240-245.